Key Developments In 2008 For China Pharmaceutical Agents
This article was originally published in PharmAsia News
Executive Summary
With the imminent rollout of China's various medical regulatory policies, drug agents are in for tougher times this year. China Pharmaceutical News has identified several major trends in the industry. 1) Mature brands will comprise the mainstay for local agents in 2008 as the entry barrier is much lower than that for newer drugs. Foreign agents dominate new products due to their market development strengths. 2) With intensifying competition, branded products will become agents' choice as savvy consumers increasingly opt for brand names that promise safety and reliability. 3) Agents are switching from single-product to multiproduct strategy to meet rising operating costs. Selling more products to an existing customer base can grow profit with minimal investment. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.